Canton Strategic (CNTN) vs Genelux (GNLX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Canton Strategic (CNTN) has outperformed Genelux (GNLX) over the past year, losing 50.6% versus a loss of 56.3%. Genelux is the larger company by market cap ($103.4 million vs $98.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CNTN | GNLX |
|---|---|---|
| Share price | $1.21 | $2.17 |
| Market cap | $98.78M | $103.36M |
| 1-day change | -1.63% | -4.82% |
| YTD return | -60.07% | -50.23% |
| 1-year return | -50.61% | -56.25% |
| P/E ratio (TTM) | 20.17 | — |
| EPS (TTM) | $0.06 | $-0.88 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $8.00K |
| Revenue growth (YoY) | — | 0.00% |
| Net income (latest FY) | $-35.92M | $-32.15M |
| Operating margin | — | -415175.00% |
| Net margin | — | -401812.50% |
| 52-week high | $5.83 | $5.89 |
| 52-week low | $1.19 | $1.77 |
| Distance from 52-week high | -79.25% | -63.16% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +767.74% |
| Average volume | 763.63K | 333.31K |
| Shares outstanding | 81.64M | 47.63M |
| Employees | 12 | 25 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Canton Strategic
CNTN stock →Canton Strategic Holdings, Inc. focuses on advancing institutional blockchain adoption and digitizing financial markets in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
About Genelux
GNLX stock →Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees
CNTN vs GNLX FAQ
Which is bigger, Canton Strategic or Genelux?
Genelux (GNLX) is larger, with a market capitalization of $103.36M compared with $98.78M for Canton Strategic (CNTN).
Which stock has performed better over the past year, CNTN or GNLX?
CNTN returned -50.61% over the past 12 months, compared with -56.25% for GNLX (price return, excluding dividends). Past performance does not predict future results.
Are Canton Strategic and Genelux in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.